OPKO Health, Inc. (NASDAQ:OPK) Major Shareholder Opko Health, Inc. Sells 50,000 Shares

OPKO Health, Inc. (NASDAQ:OPK) major shareholder Opko Health, Inc. sold 50,000 shares of the stock in a transaction that occurred on Monday, July 22nd. The stock was sold at an average price of $32.61, for a total transaction of $1,630,500.00. Following the completion of the transaction, the insider now owns 3,333,403 shares in the company, valued at approximately $108,702,271.83. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Opko Health, Inc. also recently made the following trade(s):

• On Friday, July 19th, Opko Health, Inc. sold 25,000 shares of OPKO Health stock. The stock was sold at an average price of $32.29, for a total transaction of $807,250.00.
• On Wednesday, July 17th, Opko Health, Inc. sold 25,000 shares of OPKO Health stock. The stock was sold at an average price of $32.93, for a total transaction of $823,250.00.
• On Friday, July 5th, Opko Health, Inc. sold 36,118 shares of OPKO Health stock. The stock was sold at an average price of $28.24, for a total transaction of $1,019,972.32.
• On Wednesday, July 3rd, Opko Health, Inc. sold 14,082 shares of OPKO Health stock. The stock was sold at an average price of $28.23, for a total transaction of $397,534.86.
• On Monday, July 1st, Opko Health, Inc. sold 50,000 shares of OPKO Health stock. The stock was sold at an average price of $26.63, for a total transaction of $1,331,500.00.

OPKO Health Stock Performance

Shares of NASDAQ:OPK opened at $1.42 on Friday. OPKO Health, Inc. has a 1 year low of $0.85 and a 1 year high of $2.18. The firm has a market capitalization of $989.73 million, a price-to-earnings ratio of -4.06 and a beta of 1.65. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.91 and a quick ratio of 1.62. The business’s 50 day moving average price is $1.33 and its 200-day moving average price is $1.18.

OPKO Health (NASDAQ:OPK) last announced its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.03). The business had revenue of $173.70 million for the quarter, compared to analysts’ expectations of $182.99 million. OPKO Health had a negative net margin of 31.44% and a negative return on equity of 17.89%. During the same quarter last year, the business earned ($0.02) EPS. The company’s quarterly revenue was down 26.9% on a year-over-year basis. On average, equities research analysts forecast that OPKO Health, Inc. will post -0.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On OPKO Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new stake in OPKO Health during the 1st quarter worth $26,000. IPG Investment Advisors LLC acquired a new stake in OPKO Health during the 4th quarter worth $30,000. SlateStone Wealth LLC acquired a new stake in OPKO Health during the 1st quarter worth $31,000. Moseley Investment Management Inc. acquired a new stake in OPKO Health during the 1st quarter worth $41,000. Finally, Headlands Technologies LLC acquired a new stake in OPKO Health during the 1st quarter worth $47,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

Wall Street Analyst Weigh In

OPK has been the topic of a number of analyst reports. Piper Sandler dropped their price objective on shares of OPKO Health from $5.00 to $3.00 and set an “overweight” rating on the stock in a research note on Thursday, July 18th. StockNews.com raised shares of OPKO Health to a “sell” rating in a research note on Tuesday, June 4th. Barrington Research reiterated an “outperform” rating and set a $1.50 target price on shares of OPKO Health in a research report on Monday, April 1st. Finally, HC Wainwright reiterated a “buy” rating and set a $3.00 target price on shares of OPKO Health in a research report on Wednesday, May 8th.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.